| Vertex reports 3Q loss | |
| | |
|
BOSTON (AP) -- Vertex Pharmaceuticals Inc. (VRTX) on Wednesday reported a loss of $95.1 million in its third quarter.
On a per-share basis, the Boston-based company said it had a loss of 39 cents. Losses, adjusted for one-time gains and costs, were 13 cents per share.
The results surpassed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 28 cents per share.
The drugmaker posted revenue of $309.8 million in the period, which also topped Street forecasts. Seven analysts surveyed by Zacks expected $231.3 million.
Vertex shares have increased 1 percent since the beginning of the year, while the Standard & Poor's 500 index has increased 1.5 percent. Its shares closed Wednesday at 120.10, a rise of 5.3 percent in the last 12 months.
_____
Elements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VRTX at http://www.zacks.com/ap/VRTX
_____
Keywords: Vertex Pharmaceuticals, Earnings Report
|
|
| |
ProfileMarket IndicatorsVALUE : Projects & res.Press releasesAnnual reportRISK : Asset profileContact Cpy |
Vertex Pharma is based in United states of america. Vertex Pharma is listed in United States of America. Its market capitalisation is US$ 116.6 billions as of today (€ 104.9 billions). Its stock quote reached its lowest recent point on March 12, 2004 at US$ 10.00, and its highest recent level on September 06, 2024 at US$ 468.00. Vertex Pharma has 249 070 000 shares outstanding. |